30 mei 2017: zie ook dit artikel: 

https://kanker-actueel.nl/NL/voeding-en-voedingstoffen-kan-de-bacterie-helicobacter-pylori-voorkomen-en-elimineren-en-daarmee-een-maagzweer-en-maagkanker-voorkomen.html

8 maart 2013: onderstaande studie werd al in 2008 gepubliceerd in the Lancet. Maagkanker wordt meestal veroorzaakt door een Helicobacter pylori infectie en er is ook al veel onderzoek gedaan naar het opsporen van die infectie. Zoals blijkt uit onderstaande studie is de bestrijding van de Helicobacter pylori een succesvolle aanpak ter voorkoming van een recidief.

1: Lancet. 2008 Aug 2;372(9636):392-7. Links

Comment in:

Lancet. 2008 Aug 2;372(9636):350-2.

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.

Collaborators (88)

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Asaka M, Kikuchi S, Inatsuchi S, Arakawa T, Sakaki N, Kato T, Watanabe Y, Ohara S, Aida S, Iijima K, Nasu J, Doi T, Endo H, Shirai T, Takagi A, Inaba T, Aoyama N, Shirasaka D, Azuma T, Ishihata R, Chiba T, Nishio A, Yazumi S, Kawanami T, Sawada M, Konda Y, Okazaki K, Nakamura T, Komatsu H, Miwa J, Kaise M, Kamoshida T, Yagi K, Sato H, Fuke H, Sone Y, Satoh K, Kihira K, Kawata H, Sugano K, Fujisaki J, Yanaka A, Nakajima S, Nomura H, Mizuno M, Okada H, Furukawa K, Yamazaki Y, Kagaya T, Kasugai K, Joh T, Sasaki M, Harada K, Tsutsumi T, Aoyagi K, Maeda K, Mizumachi S, Suzuki M, Furuta T, Shirai N, Suwaki K, Matsuda M, Satomura Y, Miura M, Takahashi S, Imoto I, Horiki N, Sugiyama A, Kato T, Isomoto H, Murakami K, Fujioka T, Sugihara M, Goto H, Matsui S, Nakayama J, Katsuyama T, Sugiyama T, Haruma K, Tominaga S.

Department of Gastroenterology, Yamagata Prefectural Central Hospital, Yamagata, Japan.

BACKGROUND: The relation between Helicobacter pylori infection and gastric cancer has been proven in epidemiological studies and animal experiments. Our aim was to investigate the prophylactic effect of H pylori eradication on the development of metachronous gastric carcinoma after endoscopic resection for early gastric cancer.

METHODS: In this multi-centre, open-label, randomised controlled trial, 544 patients with early gastric cancer, either newly diagnosed and planning to have endoscopic treatment or in post-resection follow-up after endoscopic treatment, were randomly assigned to receive an H pylori eradication regimen (n=272) or control (n=272). Randomisation was done by a computer-generated randomisation list and was stratified by whether the patient was newly diagnosed or post-resection. Patients in the eradication group received lansoprazole 30 mg twice daily, amoxicillin 750 mg twice daily, and clarithromycin 200 mg twice daily for a week; those in the control group received standard care, but no treatment for H pylori. Patients were examined endoscopically at 6, 12, 24, and 36 months after allocation. The primary endpoint was diagnosis of new carcinoma at another site in the stomach. Analyses were by intention to treat. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000001169.

FINDINGS: At 3-year follow-up, metachronous gastric carcinoma had developed in nine patients in the eradication group and 24 in the control group. In the full intention-to-treat population, including all patients irrespective of length of follow-up (272 patients in each group), the odds ratio for metachronous gastric carcinoma was 0.353 (95% CI 0.161-0.775; p=0.009); in the modified intention-to-treat population, including patients with at least one post-randomisation assessment of tumour status and adjusting for loss to follow-up (255 patients in the eradication group, 250 in the control group), the hazard ratio for metachronous gastric carcinoma was 0.339 (95% CI 0.157-0.729; p=0.003). In the eradication group, 19 (7%) patients had diarrhoea and 32 (12%) had soft stools.

INTERPRETATION: Prophylactic eradication of H pylori after endoscopic resection of early gastric cancer should be used to prevent the development of metachronous gastric carcinoma.

FUNDING: Hiroshima Cancer Seminar Foundation.

PMID: 18675689 [PubMed - indexed for MEDLINE]

Plaats een reactie ...

Naam (verplicht)

Email (wordt niet gepubliceerd maar wel verplicht)

Reageer op "Helicobacter pylori bacterie: Wanneer na operatie van beginnende maagkanker de Helicobacter pylori bacterie actief wordt bestreden dan heeft dat een significant gunstig effect op het wegblijven van een recidief na drie jaar follow-up."